Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 474B 4.95B 4.31B 4.08B 3.71B 6.93B 6.97B 48.64B 18.81B 241B 18.61B 18.19B 772B P/E 2027 *
40.7x
P/E 2028 * 35.4x
Enterprise Value 474B 4.95B 4.31B 4.08B 3.71B 6.93B 6.97B 48.64B 18.81B 241B 18.61B 18.19B 772B EV / Sales 2027 *
11.1x
EV / Sales 2028 * 10x
Free-Float
24.37%
Yield 2027 *
1.05%
Yield 2028 * 1.05%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day-1.97%
1 week-3.12%
Current month-8.20%
1 month+4.13%
3 months+27.11%
6 months+16.52%
Current year+13.19%
1 week 2,755.9
Extreme 2755.9
2,878
1 month 2,691.1
Extreme 2691.1
3,120.7
Current year 2,088.1
Extreme 2088.1
3,120.7
1 year 2,088.1
Extreme 2088.1
3,120.7
3 years 1,385.05
Extreme 1385.05
3,515.7
5 years 1,227
Extreme 1227
3,515.7
10 years 962.65
Extreme 962.65
3,515.7
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Tech/Sci/R&D Officer - 08/07/2024
Director TitleAgeSince
Chairman 73 01/04/2019
Director/Board Member 65 26/03/2025
Director/Board Member 67 16/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-3.12% - - 5.04B
+0.66%+2.11%+50.85%+100.71% 1,014B
+0.84%+1.22%+52.15%+65.94% 644B
+0.28%+3.15%+19.13%+70.87% 464B
-0.36%+4.54%+38.71%+40.03% 354B
+1.52%+3.46%+20.13%+26.08% 265B
+2.41%+5.70%+9.06%+15.85% 253B
+0.42%-1.22%+37.53%+43.57% 203B
+2.48%-2.43%-24.40%-57.05% 186B
+1.54%+3.69%+33.76%+98.57% 183B
Average +0.79%+0.96%+26.32%+44.95% 396.31B
Weighted average by Cap. +0.87%+1.41%+34.94%+61.37%

Financials

2027 *2028 *
Net sales 42.57B 444M 387M 366M 333M 622M 625M 4.36B 1.69B 21.63B 1.67B 1.63B 69.25B 47.24B 493M 430M 407M 369M 690M 694M 4.84B 1.87B 24.01B 1.85B 1.81B 76.86B
Net income 11.65B 122M 106M 100M 91.14M 170M 171M 1.19B 462M 5.92B 457M 447M 18.96B 13.42B 140M 122M 115M 105M 196M 197M 1.38B 532M 6.82B 526M 515M 21.83B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
17/09/26 INR 2,799.90 -1.97% 28,739
16/09/26 INR 2,856.20 +1.32% 85,460
15/09/26 INR 2,818.90 -0.34% 39,814
11/09/26 INR 2,828.40 -0.44% 38,428
10/09/26 INR 2,840.90 -1.71% 38,562
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,800.45INR
Average target price
3,081.00INR
Spread / Average Target
+10.02%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!